Fig. 1: Schematic overview of the trial design. | Molecular Psychiatry

Fig. 1: Schematic overview of the trial design.

From: Acute cannabidiol administration reduces alcohol craving and cue-induced nucleus accumbens activation in individuals with alcohol use disorder: the double-blind randomized controlled ICONIC trial

Fig. 1: Schematic overview of the trial design.

Either cannabidiol (CBD) or placebo (PLC) was administered after a preparatory phase at the beginning of the test session, followed by a rest period. 170 min after medication administration, venous blood was drawn for determination of CBD levels, and a combined stress- and cue exposure was conducted from minute 220–240 (i.e., 180 min after medication administration) using a combination of the Trier Social Stress Test (41) and an alcohol cue exposure in a bar lab setting (for details see text). Directly afterward, an alcohol cue-reactivity functional magnetic resonance imaging task was performed to investigate cue-induced brain activation and craving.

Back to article page